SG11201400916XA - Clostridium difficile antibodies - Google Patents
Clostridium difficile antibodiesInfo
- Publication number
- SG11201400916XA SG11201400916XA SG11201400916XA SG11201400916XA SG11201400916XA SG 11201400916X A SG11201400916X A SG 11201400916XA SG 11201400916X A SG11201400916X A SG 11201400916XA SG 11201400916X A SG11201400916X A SG 11201400916XA SG 11201400916X A SG11201400916X A SG 11201400916XA
- Authority
- SG
- Singapore
- Prior art keywords
- clostridium difficile
- difficile antibodies
- antibodies
- clostridium
- difficile
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161526031P | 2011-08-22 | 2011-08-22 | |
| PCT/US2012/051948 WO2013028810A1 (en) | 2011-08-22 | 2012-08-22 | Clostridium difficile antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201400916XA true SG11201400916XA (en) | 2014-06-27 |
Family
ID=47746848
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201804809RA SG10201804809RA (en) | 2011-08-22 | 2012-08-22 | Clostridium difficile antibodies |
| SG11201400916XA SG11201400916XA (en) | 2011-08-22 | 2012-08-22 | Clostridium difficile antibodies |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201804809RA SG10201804809RA (en) | 2011-08-22 | 2012-08-22 | Clostridium difficile antibodies |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9505847B2 (en) |
| EP (1) | EP2748194A4 (en) |
| JP (1) | JP6281163B2 (en) |
| KR (1) | KR20140078633A (en) |
| CN (1) | CN103917559B (en) |
| AU (2) | AU2012298877B2 (en) |
| BR (1) | BR112014004162A2 (en) |
| CA (1) | CA2845884A1 (en) |
| HK (1) | HK1199886A1 (en) |
| SG (2) | SG10201804809RA (en) |
| WO (1) | WO2013028810A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201804809RA (en) * | 2011-08-22 | 2018-07-30 | Cnj Holdings Inc | Clostridium difficile antibodies |
| CA2866634C (en) | 2012-03-09 | 2022-07-19 | Csl Behring Ag | Compositions comprising secretory-like immunoglobulins |
| EP2636684A1 (en) * | 2012-03-09 | 2013-09-11 | CSL Behring AG | Prevention of infection |
| WO2014085749A2 (en) * | 2012-11-28 | 2014-06-05 | Cnj Holdings, Inc. | Antibodies against clostridium difficile |
| WO2014165271A2 (en) * | 2013-03-13 | 2014-10-09 | Neotope Biosciences Limited | Tau immunotherapy |
| US10160797B2 (en) | 2013-03-15 | 2018-12-25 | Sanofi Pasteur Biologics, Llc | Antibodies against Clostridium difficile toxins and methods of using the same |
| US20170226192A1 (en) * | 2014-02-19 | 2017-08-10 | Jody Berry | Methods of modulating an immune response |
| US9717711B2 (en) | 2014-06-16 | 2017-08-01 | The Lauridsen Group | Methods and compositions for treating Clostridium difficile associated disease |
| WO2017191560A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
| JP7170316B2 (en) | 2016-05-02 | 2022-11-14 | プロセナ バイオサイエンシーズ リミテッド | Tau immunotherapy |
| MY197413A (en) | 2016-05-02 | 2023-06-16 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| WO2018204546A2 (en) | 2017-05-02 | 2018-11-08 | Prothena Biosciences Limited | Antibodies recognizing tau |
| CN111263769B (en) * | 2017-07-10 | 2024-01-02 | 先天制药公司 | SIGLEC-9 neutralizing antibodies |
| BR112021016947A2 (en) | 2019-03-03 | 2021-11-03 | Prothena Biosciences Ltd | Antibodies that recognize tau |
| CN112661849B (en) * | 2020-12-17 | 2022-05-20 | 杭州贤至生物科技有限公司 | Preparation method and application of clostridium difficile recombinant protein monoclonal antibody |
| WO2023113396A1 (en) * | 2021-12-14 | 2023-06-22 | 경북대학교 산학협력단 | Use of recombinant antibacterial protein for effectively killing clostridium difficile bacteria |
| CN117720651B (en) * | 2023-12-13 | 2024-05-31 | 北京新兴四寰生物技术有限公司 | Monoclonal antibody against clostridium difficile toxin B and use thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (en) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | Chimera monoclonal antibody and its preparation |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (en) | 1984-12-04 | 1986-06-21 | Teijin Ltd | Expression of hybrid antibody gene |
| AU606320B2 (en) | 1985-11-01 | 1991-02-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| GB8727489D0 (en) | 1987-11-24 | 1987-12-23 | Connaught Lab | Detoxification of pertussis toxin |
| US5221618A (en) | 1987-11-24 | 1993-06-22 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
| US5358868A (en) | 1987-11-24 | 1994-10-25 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
| US5244657A (en) | 1987-11-24 | 1993-09-14 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
| US5332583A (en) | 1987-11-24 | 1994-07-26 | Connaught Laboratories Limited | Vaccine containing genetically-detoxified pertussis holotoxin |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5736139A (en) * | 1989-10-31 | 1998-04-07 | Ochidian Pharmaceuticals, Inc. | Treatment of Clostridium difficile induced disease |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5231003A (en) | 1990-05-11 | 1993-07-27 | Cambridge Bioscience Corporation | Monoclonal antibodies specific for toxin b of clostridium difficile |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69233482T2 (en) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US5908635A (en) | 1994-08-05 | 1999-06-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the liposomal delivery of nucleic acids |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| US6096716A (en) | 1994-12-12 | 2000-08-01 | The Board Of Regents, The University Of Texas System | Liposome-mediated transfection of central nervous system cells |
| AUPO517897A0 (en) | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
| DE19739685A1 (en) * | 1997-09-10 | 1999-03-11 | Eichel Streiber Christoph Von | Monoclonal antibodies for the therapy and prophylaxis of diseases caused by Clostridium difficile |
| AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
| NZ513935A (en) | 1999-02-17 | 2004-02-27 | Csl Ltd | Immunogenic complexes and methods relating thereto |
| US20040126829A1 (en) | 2001-12-18 | 2004-07-01 | Hildebrand William H. | Anti-HLA assay and methods |
| GB0309126D0 (en) | 2003-04-17 | 2003-05-28 | Neutec Pharma Plc | Clostridium difficile focussed antibodies |
| AU2005320349C1 (en) * | 2004-02-06 | 2019-06-13 | E. R. Squibb & Sons, L.L.C. | Antibodies against clostridium difficile toxins and uses thereof |
| EP2484374A1 (en) | 2004-07-18 | 2012-08-08 | CSL Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
| US20070129320A9 (en) | 2004-07-18 | 2007-06-07 | Coley Pharmaceutical Group, Ltd. | Methods and compositions for inducing innate immune responses |
| WO2006044643A2 (en) | 2004-10-15 | 2006-04-27 | Seattle Genetics, Inc. | Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| CA2592015A1 (en) * | 2004-12-27 | 2006-07-06 | Progenics Pharmaceuticals (Nevada), Inc. | Orally deliverable and anti-toxin antibodies and methods for making and using them |
| US7790203B2 (en) | 2005-12-13 | 2010-09-07 | Lowder Tom R | Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions |
| SG170091A1 (en) * | 2006-03-10 | 2011-04-29 | Wyeth Corp | Anti-5t4 antibodies and uses thereof |
| SG177168A1 (en) * | 2006-12-01 | 2012-01-30 | Medarex Inc | Human antibodies that bind cd22 and uses thereof |
| US7597891B2 (en) | 2006-12-13 | 2009-10-06 | Simon Michael R | Synthesis of human secretory IgA for the treatment of Clostridium difficile associated diseases |
| JPWO2008114733A1 (en) * | 2007-03-16 | 2010-07-01 | 協和発酵キリン株式会社 | Anti-Claudin-4 antibody |
| CA2705292C (en) * | 2007-11-13 | 2016-06-21 | Teva Biopharmaceuticals Usa, Inc. | Humanized antibodies against tl1a |
| SG187457A1 (en) | 2008-01-11 | 2013-02-28 | Univ Tokyo | Anti-cldn6 antibody |
| US7740844B2 (en) * | 2008-04-29 | 2010-06-22 | Taiwan Liposome Co. Ltd | Anti-VEGF monoclonal antibody |
| GB0921288D0 (en) * | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
| ES2757675T3 (en) | 2010-04-15 | 2020-04-29 | Progenics Pharm Inc | Antibodies for the treatment of Clostridium difficile infection and disease |
| SG10201804809RA (en) * | 2011-08-22 | 2018-07-30 | Cnj Holdings Inc | Clostridium difficile antibodies |
-
2012
- 2012-08-22 SG SG10201804809RA patent/SG10201804809RA/en unknown
- 2012-08-22 KR KR1020147007742A patent/KR20140078633A/en not_active Application Discontinuation
- 2012-08-22 AU AU2012298877A patent/AU2012298877B2/en not_active Ceased
- 2012-08-22 CN CN201280051860.7A patent/CN103917559B/en not_active Expired - Fee Related
- 2012-08-22 SG SG11201400916XA patent/SG11201400916XA/en unknown
- 2012-08-22 JP JP2014527278A patent/JP6281163B2/en not_active Expired - Fee Related
- 2012-08-22 WO PCT/US2012/051948 patent/WO2013028810A1/en active Application Filing
- 2012-08-22 BR BR112014004162A patent/BR112014004162A2/en not_active Application Discontinuation
- 2012-08-22 CA CA2845884A patent/CA2845884A1/en not_active Abandoned
- 2012-08-22 US US13/592,286 patent/US9505847B2/en not_active Expired - Fee Related
- 2012-08-22 EP EP12826134.4A patent/EP2748194A4/en not_active Withdrawn
-
2015
- 2015-01-09 HK HK15100250.8A patent/HK1199886A1/en not_active IP Right Cessation
-
2016
- 2016-10-31 US US15/338,990 patent/US9994630B2/en not_active Expired - Fee Related
-
2018
- 2018-03-28 AU AU2018202199A patent/AU2018202199A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6281163B2 (en) | 2018-02-21 |
| WO2013028810A1 (en) | 2013-02-28 |
| US9994630B2 (en) | 2018-06-12 |
| EP2748194A1 (en) | 2014-07-02 |
| NZ622798A (en) | 2016-09-30 |
| US9505847B2 (en) | 2016-11-29 |
| BR112014004162A2 (en) | 2018-04-24 |
| CN103917559B (en) | 2018-01-12 |
| HK1199886A1 (en) | 2015-07-24 |
| CA2845884A1 (en) | 2013-02-28 |
| AU2018202199A1 (en) | 2018-04-26 |
| CN103917559A (en) | 2014-07-09 |
| US20170051047A1 (en) | 2017-02-23 |
| KR20140078633A (en) | 2014-06-25 |
| AU2012298877A1 (en) | 2014-03-13 |
| US20140004118A1 (en) | 2014-01-02 |
| SG10201804809RA (en) | 2018-07-30 |
| JP2014529610A (en) | 2014-11-13 |
| EP2748194A4 (en) | 2015-01-28 |
| AU2012298877B2 (en) | 2018-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274595A (en) | Antibodies specific for tgf-beta | |
| HRP20180640T1 (en) | Anti-b7-h3 antibody | |
| IL259826A (en) | Anti-alphabetatcr antibody | |
| HK1199886A1 (en) | Clostridium difficile antibodies | |
| GB201103955D0 (en) | Antibodies | |
| GB201112056D0 (en) | Antibodies | |
| GB201016742D0 (en) | Clostridium difficile antigens | |
| AP2014007571A0 (en) | Anti IL-36R antibodies | |
| HK1202805A1 (en) | Clostridium difficile antigens | |
| HK1216999A1 (en) | Antibodies against clostridium difficile | |
| IL232957A0 (en) | Clostridium difficile toxin-based vaccine | |
| EP2683729A4 (en) | Aptamers for clostridium difficile diagnostics | |
| TWI563004B (en) | Anti-hxcr1 antibody | |
| IL237172A0 (en) | פוליפפטידים של clostridium difficile כתרכיבים | |
| EP2714074A4 (en) | Anti-emr1 antibodies | |
| EP2769988A4 (en) | Anti-gap43 antibody | |
| IL231661A0 (en) | Clostridium difficile antibodies | |
| GB201121149D0 (en) | Clostridium difficile toxin-based vaccine |